List of Spritam drug patents

Spritam is owned by Aprecia Pharms.

Spritam contains Levetiracetam.

Spritam has a total of 3 drug patents out of which 0 drug patents have expired.

Spritam was authorised for market use on 31 July, 2015.

Spritam is available in tablet, for suspension;oral dosage forms.

Spritam can be used as method of administering levetiracetam, method of administering levetiracetam under fasted conditions; method of administering levetiracetam; method of administering levetiracetam under fed conditions.

The generics of Spritam are possible to be released after 14 March, 2034.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9339489 APRECIA PHARMS Rapid disperse dosage form containing levetiracetam
Mar, 2034

(10 years from now)

US9669009 APRECIA PHARMS Rapid disperse dosage form containing levetiracetam
Mar, 2034

(10 years from now)

US11160786 APRECIA PHARMS Rapid disperse dosage form
Mar, 2034

(10 years from now)

Drugs and Companies using LEVETIRACETAM ingredient

Market Authorisation Date: 31 July, 2015

Treatment: Method of administering levetiracetam; Method of administering levetiracetam under fasted conditions; Method of administering levetiracetam under fed conditions

Dosage: TABLET, FOR SUSPENSION;ORAL

More Information on Dosage

SPRITAM family patents

7

United States

3

Japan

2

Hong Kong

2

Australia

2

Spain

2

China

2

European Union

1

Canada

1

Mexico

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in